DK1412493T3 - Fremgangsmåder og sammensætninger der angår forbedrede lentiviral-vektor.-produktionsystemer - Google Patents
Fremgangsmåder og sammensætninger der angår forbedrede lentiviral-vektor.-produktionsystemerInfo
- Publication number
- DK1412493T3 DK1412493T3 DK02763401.3T DK02763401T DK1412493T3 DK 1412493 T3 DK1412493 T3 DK 1412493T3 DK 02763401 T DK02763401 T DK 02763401T DK 1412493 T3 DK1412493 T3 DK 1412493T3
- Authority
- DK
- Denmark
- Prior art keywords
- vectors
- production systems
- promoters
- methods
- lentiviral vector
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16051—Methods of production or purification of viral material
- C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16061—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/38—Vector systems having a special element relevant for transcription being a stuffer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30956901P | 2001-08-02 | 2001-08-02 | |
PCT/US2002/024275 WO2003012054A2 (en) | 2001-08-02 | 2002-08-01 | Methods and compositions relating to improved lentiviral vector production systems |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1412493T3 true DK1412493T3 (da) | 2012-01-09 |
Family
ID=23198746
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK02763401.3T DK1412493T3 (da) | 2001-08-02 | 2002-08-01 | Fremgangsmåder og sammensætninger der angår forbedrede lentiviral-vektor.-produktionsystemer |
Country Status (8)
Country | Link |
---|---|
US (3) | US7629153B2 (da) |
EP (1) | EP1412493B1 (da) |
AT (1) | ATE527347T1 (da) |
AU (1) | AU2002327412A1 (da) |
CA (1) | CA2456169C (da) |
DK (1) | DK1412493T3 (da) |
IL (2) | IL160132A0 (da) |
WO (1) | WO2003012054A2 (da) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7575924B2 (en) | 2000-11-13 | 2009-08-18 | Research Development Foundation | Methods and compositions relating to improved lentiviral vectors and their applications |
ATE527347T1 (de) | 2001-08-02 | 2011-10-15 | Inst Clayton De La Rech | Verfahren und zusammensetzungen im zusammenhang mit verbesserten lentivirusvektor- produktionssystemen |
JP2005504539A (ja) * | 2001-10-02 | 2005-02-17 | インスティテュット クレイトン ド ラ リシェルシュ | 制限発現レンチウイルス性ベクターに関連する方法及び組成物並びにその応用 |
GB0702695D0 (en) * | 2007-02-12 | 2007-03-21 | Ark Therapeutics Ltd | Production of vectors |
GB0702694D0 (en) * | 2007-02-12 | 2007-03-21 | Ark Therapeutics Ltd | Vectors |
CA2689913C (en) | 2007-06-06 | 2014-10-07 | Research Development Foundation | Rtef-1 variants and the use thereof for inhibition of angiogenesis |
EP2560672B1 (en) | 2010-04-19 | 2014-03-05 | Research Development Foundation | Rtef-1 variants and uses thereof |
TWI702955B (zh) | 2012-05-15 | 2020-09-01 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
US20150224181A1 (en) | 2012-09-14 | 2015-08-13 | The United States Of America As Represented By The Secretary Department Of Health And Human Se | Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use |
EP2912186B1 (en) | 2012-10-24 | 2021-01-06 | Platelet Targeted Therapeutics LLC | Platelet targeted treatment |
GB201318804D0 (en) * | 2013-10-24 | 2013-12-11 | Adaptimmune Ltd | Vectors for transgene expression |
CN106414474B (zh) | 2014-03-17 | 2021-01-15 | 阿德夫拉姆生物技术股份有限公司 | 用于视锥细胞中增强的基因表达的组合物和方法 |
BR112017001311A2 (pt) | 2014-09-07 | 2017-11-14 | Selecta Biosciences Inc | métodos e composições para atenuar as respostas imunes do vetor de transferência anti-viral de salto de éxon |
WO2016141078A1 (en) | 2015-03-02 | 2016-09-09 | Avalanche Biotechnologies, Inc. | Compositions and methods for intravitreal delivery of polynucleotides to retinal cones |
EP3331554B1 (en) | 2015-08-03 | 2022-05-11 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Brachyury deletion mutants, non-yeast vectors encoding brachyury deletion mutants, and their use |
GB2545763A (en) | 2015-12-23 | 2017-06-28 | Adverum Biotechnologies Inc | Mutant viral capsid libraries and related systems and methods |
EP3211000B1 (en) | 2016-02-25 | 2019-01-30 | Provecs Medical GmbH | Novel immunostimulating vector system |
EP3443001A4 (en) | 2016-04-11 | 2020-04-29 | Obsidian Therapeutics, Inc. | REGULATED BIOCIRCUIT SYSTEMS |
BR112018071695A2 (pt) | 2016-04-20 | 2019-02-19 | Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas | composições e métodos para a expressão gênica acentuada de pklr |
EP4049683A1 (en) | 2016-04-29 | 2022-08-31 | Adverum Biotechnologies, Inc. | Evasion of neutralizing antibodies by a recombinant adeno-associated virus |
US11192925B2 (en) | 2016-10-19 | 2021-12-07 | Adverum Biotechnologies, Inc. | Modified AAV capsids and uses thereof |
US20180193482A1 (en) | 2017-01-07 | 2018-07-12 | Selecta Biosciences, Inc. | Patterned dosing of immunosuppressants coupled to synthetic nanocarriers |
US10675328B2 (en) | 2017-02-14 | 2020-06-09 | Children's Hospital Medical Center | Compositions and methods for treatment of Gcase related disease states |
SG11201907653QA (en) | 2017-03-17 | 2019-09-27 | Adverum Biotechnologies Inc | Compositions and methods for enhanced gene expression |
SG11201908280SA (en) | 2017-03-30 | 2019-10-30 | Univ Queensland | "chimeric molecules and uses thereof" |
GB201706394D0 (en) | 2017-04-21 | 2017-06-07 | Ospedale San Raffaele Srl | Gene Therapy |
CN110945146B (zh) * | 2017-10-03 | 2023-12-26 | 雅培分子公司 | 检测人类免疫缺陷病毒(hiv)的测定法 |
WO2019075360A1 (en) | 2017-10-13 | 2019-04-18 | Selecta Biosciences, Inc. | METHODS AND COMPOSITIONS FOR MITIGATING ANTI-VECTOR VIRAL TRANSFER IGM RESPONSES |
AU2018352583A1 (en) | 2017-10-16 | 2020-04-09 | Centro de Investigaciones Energeticas, Medioambientales Y Tecnologicas, O.A., M.P. | Lentiviral vectors for delivery of PKLR to treat pyruvate kinase deficiency |
CA3084633A1 (en) | 2017-12-21 | 2019-06-27 | Crispr Therapeutics Ag | Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp) |
CN111836892A (zh) | 2017-12-21 | 2020-10-27 | 克里斯珀医疗股份公司 | 用于治疗2a型乌谢尔综合征的材料和方法 |
KR20200139679A (ko) | 2018-02-26 | 2020-12-14 | 안톨알엑스, 인크. | 면역관용성 리포솜 및 그의 사용 방법 |
US20220403001A1 (en) | 2018-06-12 | 2022-12-22 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
JPWO2020059848A1 (ja) * | 2018-09-20 | 2021-10-07 | 国立大学法人 東京医科歯科大学 | レンチウイルスベクター産生の増強方法 |
EP3870600A1 (en) | 2018-10-24 | 2021-09-01 | Obsidian Therapeutics, Inc. | Er tunable protein regulation |
EP3894011A1 (en) | 2018-12-11 | 2021-10-20 | Obsidian Therapeutics, Inc. | Membrane bound il12 compositions and methods for tunable regulation |
AU2020236937B2 (en) | 2019-03-08 | 2023-06-15 | Obsidian Therapeutics, Inc. | CD40L compositions and methods for tunable regulation |
US20230026259A1 (en) | 2019-03-08 | 2023-01-26 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
KR20220004121A (ko) | 2019-04-28 | 2022-01-11 | 셀렉타 바이오사이언시즈, 인크. | 바이러스 전달 벡터에 대한 기존의 면역을 갖는 대상체의 치료 방법 |
WO2020227515A1 (en) | 2019-05-07 | 2020-11-12 | Voyager Therapeutics, Inc. | Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation |
JP2022534741A (ja) | 2019-05-28 | 2022-08-03 | セレクタ バイオサイエンシーズ インコーポレーテッド | 減弱化された抗ウイルス導入ベクター免疫応答のための方法および組成物 |
US20220259284A1 (en) | 2019-06-12 | 2022-08-18 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
WO2020252404A1 (en) | 2019-06-12 | 2020-12-17 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
US20230092895A1 (en) | 2019-08-30 | 2023-03-23 | Obsidian Therapeutics, Inc. | Tandem cd19 car-based compositions and methods for immunotherapy |
WO2021046451A1 (en) | 2019-09-06 | 2021-03-11 | Obsidian Therapeutics, Inc. | Compositions and methods for dhfr tunable protein regulation |
EP4028413A1 (en) | 2019-09-10 | 2022-07-20 | Obsidian Therapeutics, Inc. | Ca2-il15 fusion proteins for tunable regulation |
WO2021072129A2 (en) | 2019-10-08 | 2021-04-15 | Trustees Of Boston College | Proteins containing multiple, different unnatural amino acids and methods of making and using such proteins |
EP4087861A1 (en) | 2020-01-08 | 2022-11-16 | Obsidian Therapeutics, Inc. | Compositions and methods for tunable regulation of transcription |
MX2022010936A (es) | 2020-03-05 | 2022-11-16 | Neotx Therapeutics Ltd | ³métodos y composiciones para el tratamiento del cáncer con células inmunológicas. |
AU2021320902A1 (en) | 2020-08-07 | 2023-04-06 | Spacecraft Seven, Llc | Plakophilin-2 (PKP2) gene therapy using AAV vector |
WO2022060806A1 (en) | 2020-09-16 | 2022-03-24 | Obsidian Therapeutics, Inc. | Compositions and methods for expression of anti-bcma chimeric antigen receptors with small molecule-regulated il15 in t cells |
AU2021202658A1 (en) | 2021-04-28 | 2022-11-17 | Fondazione Telethon | Gene therapy |
WO2022235929A1 (en) | 2021-05-05 | 2022-11-10 | Radius Pharmaceuticals, Inc. | Animal model having homologous recombination of mouse pth1 receptor |
CA3225985A1 (en) | 2021-07-01 | 2023-01-05 | Indapta Therapeutics, Inc. | Engineered natural killer (nk) cells and related methods |
WO2023019226A1 (en) | 2021-08-11 | 2023-02-16 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy |
AU2022325232A1 (en) | 2021-08-11 | 2024-02-08 | Sana Biotechnology, Inc. | Genetically modified primary cells for allogeneic cell therapy |
AU2022325955A1 (en) | 2021-08-11 | 2024-02-08 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions |
WO2023019227A1 (en) | 2021-08-11 | 2023-02-16 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions |
US20230141563A1 (en) | 2021-10-12 | 2023-05-11 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector igm responses |
WO2023114918A1 (en) | 2021-12-16 | 2023-06-22 | Ludwig Institute For Cancer Research Ltd | Antisense transfer vectors and methods of use thereof |
WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
WO2023150647A1 (en) | 2022-02-02 | 2023-08-10 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
WO2023158836A1 (en) | 2022-02-17 | 2023-08-24 | Sana Biotechnology, Inc. | Engineered cd47 proteins and uses thereof |
WO2023172624A1 (en) | 2022-03-09 | 2023-09-14 | Selecta Biosciences, Inc. | Immunosuppressants in combination with anti-igm agents and related dosing |
WO2023173123A1 (en) | 2022-03-11 | 2023-09-14 | Sana Biotechnology, Inc. | Genetically modified cells and compositions and uses thereof |
GB202206346D0 (en) | 2022-04-29 | 2022-06-15 | Ospedale San Raffaele Srl | Gene therapy |
WO2024007020A1 (en) | 2022-06-30 | 2024-01-04 | Indapta Therapeutics, Inc. | Combination of engineered natural killer (nk) cells and antibody therapy and related methods |
WO2024026377A1 (en) | 2022-07-27 | 2024-02-01 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308236D0 (en) * | 1983-03-25 | 1983-05-05 | Celltech Ltd | Dna vectors |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4682195A (en) * | 1985-09-30 | 1987-07-21 | General Electric Company | Insulated gate device with configured emitter contact pad |
US5019384A (en) * | 1986-06-30 | 1991-05-28 | Massachusetts Institute Of Technology | Immunonodulating compositions and their use |
EP0266032A1 (en) | 1986-08-29 | 1988-05-04 | Beecham Group Plc | Modified fibrinolytic enzyme |
NL8603180A (nl) * | 1986-12-15 | 1988-07-01 | Philips Nv | Meerkleurenafbeeldinrichting, voorzien van een beheerinrichting voor kleurselektie. |
US5466468A (en) * | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
CA2051288C (en) | 1990-09-14 | 2002-02-05 | Robert L. Martuza | Viral targeted destruction of neoplastic cells |
US5885570A (en) * | 1991-01-23 | 1999-03-23 | The General Hospital Corporation | Induction of tolerance with modified immunogens |
DE4204650C1 (da) * | 1992-02-15 | 1993-07-08 | Hoffmeister, Helmut, Dr., 4400 Muenster, De | |
DE4228457A1 (de) * | 1992-08-27 | 1994-04-28 | Beiersdorf Ag | Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen |
US5834256A (en) * | 1993-06-11 | 1998-11-10 | Cell Genesys, Inc. | Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells |
US5912411A (en) * | 1993-06-14 | 1999-06-15 | University Of Heidelberg | Mice transgenic for a tetracycline-inducible transcriptional activator |
US6013517A (en) * | 1994-05-09 | 2000-01-11 | Chiron Corporation | Crossless retroviral vectors |
FR2722208B1 (fr) * | 1994-07-05 | 1996-10-04 | Inst Nat Sante Rech Med | Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique |
US5599302A (en) * | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
GB9510272D0 (en) * | 1995-05-22 | 1995-07-19 | Isis Innovation | Retroviral vectors |
US6013516A (en) * | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
US5705629A (en) * | 1995-10-20 | 1998-01-06 | Hybridon, Inc. | Methods for H-phosphonate synthesis of mono- and oligonucleotides |
GB9525639D0 (en) * | 1995-12-15 | 1996-02-14 | Isis Innovation | Improved retroviral vectors |
US5928906A (en) * | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
HUP0000421A2 (hu) * | 1996-10-17 | 2000-06-28 | Oxford Biomedica (Uk) Limited | Retrovirális vektorok |
GB9621680D0 (en) * | 1996-10-17 | 1996-12-11 | Oxford Biomedica Ltd | Lentiviral vectors |
US5846225A (en) * | 1997-02-19 | 1998-12-08 | Cornell Research Foundation, Inc. | Gene transfer therapy delivery device and method |
US6017758A (en) | 1997-02-20 | 2000-01-25 | Vanderbilt University | DMNPE caged nucleic acid and vector |
WO1998039463A2 (en) * | 1997-03-06 | 1998-09-11 | Ueberla Klaus | Lentivirus based vector and vector system |
US6531123B1 (en) * | 1997-05-01 | 2003-03-11 | Lung-Ji Chang | Lentiviral vectors |
US6207455B1 (en) | 1997-05-01 | 2001-03-27 | Lung-Ji Chang | Lentiviral vectors |
KR100556864B1 (ko) | 1997-05-13 | 2006-03-10 | 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 | 렌티바이러스-기원 유전자 전달 벡터 |
US5981830A (en) * | 1997-05-30 | 1999-11-09 | Schering Aktiengesellschaft | Knockout mice and their progeny with a disrupted hepsin gene |
CA2292760A1 (en) * | 1997-06-04 | 1998-12-10 | Oxford Biomedica (Uk) Limited | Vector |
US5972650A (en) | 1997-06-26 | 1999-10-26 | Brigham And Women's Hospital | Tetracycline repressor regulated mammalian cell transcription and viral replication switch |
WO1999004026A2 (en) | 1997-07-18 | 1999-01-28 | Chiron Corporation | Lentiviral vectors |
US6136597A (en) * | 1997-09-18 | 2000-10-24 | The Salk Institute For Biological Studies | RNA export element |
US5994136A (en) * | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
DK1895010T3 (da) * | 1997-12-22 | 2011-11-21 | Oxford Biomedica Ltd | Vektorer baseret på virus for infektiøs hesteanæmi (eiav) |
WO1999036511A2 (en) | 1998-01-16 | 1999-07-22 | Chiron Corporation | Feline immunodeficiency virus gene therapy vectors |
US20020048805A1 (en) * | 1998-01-16 | 2002-04-25 | Julie C. Johnston | Feline immunodeficiency virus gene therapy vectors |
US6084063A (en) | 1998-02-06 | 2000-07-04 | The United States Of America As Represented By The Department Of Health And Human Services | Signal transduction inhibitors of allergic reactions |
US6218181B1 (en) | 1998-03-18 | 2001-04-17 | The Salk Institute For Biological Studies | Retroviral packaging cell line |
WO1999051754A1 (en) | 1998-04-02 | 1999-10-14 | Dana-Farber Cancer Institute, Inc. | Infectious pseudotyped lentiviral vectors lacking matrix protein and uses thereof |
FR2777909B1 (fr) * | 1998-04-24 | 2002-08-02 | Pasteur Institut | Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex |
US6555342B1 (en) | 1998-06-03 | 2003-04-29 | Uab Research Foundation | Fusion protein delivery system and uses thereof |
US5989910A (en) * | 1998-08-03 | 1999-11-23 | University Of Lausanne | Potent genetic switch allowing regulated gene expression in eukaryotic cells |
WO2000012737A1 (en) | 1998-08-26 | 2000-03-09 | Bavarian Nordic Research Institute A/S | Guanylate binding protein (gbp-1) as inhibitor of cell proliferation and molecular marker for the determination of the stage of cellular differentiation |
WO2000015819A1 (en) | 1998-09-11 | 2000-03-23 | The Children's Medical Center Corporation | Packaging cell lines for hiv-derived retroviral vector particles |
EP1932426A1 (en) * | 1998-10-01 | 2008-06-18 | University of Southern California | Gene delivery system and methods of use |
GB9825524D0 (en) * | 1998-11-20 | 1999-01-13 | Oxford Biomedica Ltd | Vector |
DE19856463B4 (de) * | 1998-11-26 | 2006-02-02 | Heinrich-Pette-Institut | Retrovirale, mit LCMV pseudotypisierte Hybrid-Vektoren |
EP1165842A4 (en) | 1999-03-16 | 2004-07-07 | Dana Farber Cancer Inst Inc | LENTIVIRAL VECTOR SYSTEMS FOR SCREENING LARGE QUANTITIES |
US6271359B1 (en) | 1999-04-14 | 2001-08-07 | Musc Foundation For Research Development | Tissue-specific and pathogen-specific toxic agents and ribozymes |
JP2002542834A (ja) | 1999-04-29 | 2002-12-17 | アールフス・ユニバーシティー | レトロウイルスベクターでのires転写カセットからの異種遺伝子群の発現 |
EP1059357A1 (en) * | 1999-06-09 | 2000-12-13 | Universite Pierre Et Marie Curie Paris Vi | Replicating or semi-replicating retroviral constructs, preparation and uses for gene delivery |
ES2447115T3 (es) | 1999-10-11 | 2014-03-11 | Institut Pasteur | Vectores para la preparación de composiciones inmunoterapéuticas |
WO2001027304A2 (en) * | 1999-10-12 | 2001-04-19 | Institut Pasteur | Lentiviral triplex dna, and vectors and recombinant cells containing lentiviral triplex dna |
JP2003517301A (ja) | 1999-11-10 | 2003-05-27 | ザ ユーエービー リサーチ ファウンデイション | 造血幹細胞のレンチウイルスベクター形質導入 |
US6218186B1 (en) | 1999-11-12 | 2001-04-17 | Trustees Of The University Of Pennsylvania | HIV-MSCV hybrid viral vector for gene transfer |
DE60043870D1 (de) | 1999-12-14 | 2010-04-01 | Novartis Ag | Auf bovinem Immundefizienvirus (BIV) basierende Vektoren |
US6864085B2 (en) | 1999-12-14 | 2005-03-08 | Novartis Ag | Bovine immunodeficiency virus (BIV) based vectors |
WO2001055369A1 (en) | 2000-01-28 | 2001-08-02 | The Scripps Research Institute | Synthetic internal ribosome entry sites and methods of identifying same |
CA2403397A1 (en) | 2000-03-16 | 2001-09-20 | Genetica, Inc. | Methods and compositions for rna interference |
IL152527A0 (en) | 2000-05-12 | 2003-05-29 | Univ Southern California | Retroviral vectors comprising an enhanced 3'transcription termination structure |
WO2001092506A1 (en) | 2000-05-30 | 2001-12-06 | University Of Rochester | Siv derived lentiviral vector systems |
US7575924B2 (en) | 2000-11-13 | 2009-08-18 | Research Development Foundation | Methods and compositions relating to improved lentiviral vectors and their applications |
US20020160393A1 (en) * | 2000-12-28 | 2002-10-31 | Symonds Geoffrey P. | Double-stranded RNA-mediated gene suppression |
US20020132257A1 (en) | 2001-01-31 | 2002-09-19 | Tony Giordano | Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell |
WO2002066638A1 (fr) | 2001-02-22 | 2002-08-29 | Gencom Corporation | Gene recombinant contenant une sequence de repetition inversee et utilisation correspondante |
US20030039636A1 (en) | 2001-05-01 | 2003-02-27 | Genetix Pharmaceuticals, Inc. | Novel self-inactivating (SIN) lentiviral vectors |
ATE527347T1 (de) * | 2001-08-02 | 2011-10-15 | Inst Clayton De La Rech | Verfahren und zusammensetzungen im zusammenhang mit verbesserten lentivirusvektor- produktionssystemen |
US20030119770A1 (en) * | 2001-08-02 | 2003-06-26 | Zhennan Lai | Intercellular delivery of a herpes simplex virus VP22 fusion protein from cells infected with lentiviral vectors |
WO2003022052A1 (en) | 2001-09-13 | 2003-03-20 | California Institute Of Technology | Method for expression of small rna molecules within a cell |
WO2003072788A1 (en) | 2002-02-21 | 2003-09-04 | The Wistar Institute Of Anatomy And Biology | Methods and compositions for reversibly controlling expression of target genes in cells |
-
2002
- 2002-08-01 AT AT02763401T patent/ATE527347T1/de not_active IP Right Cessation
- 2002-08-01 IL IL16013202A patent/IL160132A0/xx unknown
- 2002-08-01 DK DK02763401.3T patent/DK1412493T3/da active
- 2002-08-01 EP EP02763401A patent/EP1412493B1/en not_active Expired - Lifetime
- 2002-08-01 WO PCT/US2002/024275 patent/WO2003012054A2/en not_active Application Discontinuation
- 2002-08-01 CA CA2456169A patent/CA2456169C/en not_active Expired - Lifetime
- 2002-08-01 AU AU2002327412A patent/AU2002327412A1/en not_active Abandoned
- 2002-08-01 US US10/209,952 patent/US7629153B2/en not_active Expired - Lifetime
-
2004
- 2004-01-29 IL IL160132A patent/IL160132A/en active IP Right Grant
-
2009
- 2009-10-13 US US12/578,346 patent/US8900858B2/en not_active Expired - Lifetime
-
2014
- 2014-10-28 US US14/525,520 patent/US9260725B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
ATE527347T1 (de) | 2011-10-15 |
CA2456169A1 (en) | 2003-02-13 |
US7629153B2 (en) | 2009-12-08 |
EP1412493A2 (en) | 2004-04-28 |
WO2003012054A3 (en) | 2003-11-20 |
EP1412493B1 (en) | 2011-10-05 |
WO2003012054A2 (en) | 2003-02-13 |
US9260725B2 (en) | 2016-02-16 |
US20100062524A1 (en) | 2010-03-11 |
AU2002327412A1 (en) | 2003-02-17 |
CA2456169C (en) | 2012-05-22 |
US20150203870A1 (en) | 2015-07-23 |
IL160132A0 (en) | 2004-06-20 |
US8900858B2 (en) | 2014-12-02 |
EP1412493A4 (en) | 2005-11-23 |
IL160132A (en) | 2012-01-31 |
US20030082789A1 (en) | 2003-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1412493T3 (da) | Fremgangsmåder og sammensætninger der angår forbedrede lentiviral-vektor.-produktionsystemer | |
Zhang et al. | Transcriptional repression by the BRG1-SWI/SNF complex affects the pluripotency of human embryonic stem cells | |
Moelling et al. | RNase H as gene modifier, driver of evolution and antiviral defense | |
Park et al. | Staufen‐mediated mRNA decay | |
Kushwaha et al. | The replication initiator protein of a geminivirus interacts with host monoubiquitination machinery and stimulates transcription of the viral genome | |
ATE484596T1 (de) | Mutantes herpes-simplex-virus und verwendung davon bei der behandlung von plattenepithelkarzinom | |
BR112021006844A2 (pt) | métodos para editar um rna alvo e para tratar ou prevenir uma doença ou condição, rna editado ou uma célula hospedeira tendo um rna editado, rna que recruta desaminase, construção, biblioteca, composição, célula hospedeira, e, kit para editar um rna alvo . | |
Cheng et al. | Signatures of host mRNA 5′ terminus for efficient hantavirus cap snatching | |
BR112018010635A2 (pt) | linhagens celulares estáveis para a produção retroviral | |
JP2019531068A5 (da) | ||
BRPI0514396A2 (pt) | polipeptìdeos dependentes de vitamina k modificada | |
NO20074654L (no) | Lenteviral-vektorer og deres anvendelse | |
CL2020002704A1 (es) | Terapia de gen para enfermedades causadas por combinaciones desequilibradas de nucleótidos que incluyen síndromes de agotamiento de adn mitocondrial | |
Valdmanis et al. | The expanding repertoire of circular RNAs | |
HUP0301356A2 (hu) | Új, DPPIV-gyel rokon szerin proteáz gének | |
CO6270367A2 (es) | Genes de dc-sign icam-3 y lsectin porcinas y usos de los mismos | |
JP2018534937A5 (da) | ||
Geerts-Dimitriadou et al. | Analysis of the Tomato spotted wilt virus ambisense S RNA-encoded hairpin structure in translation | |
Berry et al. | Viral suppressors of RNA silencing hinder exogenous and endogenous small RNA pathways in Drosophila | |
Sofuku et al. | Transcription profiling demonstrates epigenetic control of non-retroviral RNA virus-derived elements in the human genome | |
Brown et al. | Robust, reversible gene knockdown using a single lentiviral short hairpin RNA vector | |
Le Mercier et al. | A novel expression cassette of lyssavirus shows that the distantly related Mokola virus can rescue a defective rabies virus genome | |
Oliveira et al. | Animal models of mitochondrial DNA transactions in disease and ageing | |
Aurélie et al. | Lentiviral vectors: a powerful tool to target astrocytes in vivo | |
Jang et al. | Regulation of BC 200 RNA‐mediated translation inhibition by hn RNP E1 and E2 |